✓ Translated by DotMD AI Clinical Council Source: Journal of the renin-angiotensin-aldosterone system : JRAAS • Randomized Controlled Trial
Verify Primary Source: NIH PubMed PMID #22546623 ↗

Randomized Controlled Trial: A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients (N = 70)

Original Paper Title: “A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
N = 70
Evidence Classification
Randomized Controlled Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • Telmisartan was significantly more effective than carvedilol in preventing recurrent AF episodes in hypertensive AF patients, despite a similar lowering of blood pressure.
  • Study Design & Sample: Randomized Controlled Trial published in Journal of the renin-angiotensin-aldosterone system : JRAAS (N = 70 human participants).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Journal of the renin-angiotensin-aldosterone system : JRAAS (2012), this randomized controlled trial evaluating 70 human participants investigated: Atrial remodelling, leading to atrial fibrillation (AF), is mediated by the renin-angiotensin-aldosterone system. Key clinical takeaway: Telmisartan was significantly more effective than carvedilol in preventing recurrent AF episodes in hypertensive AF patients, despite a similar lowering of blood pressure.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Journal of the renin-angiotensin-aldosterone system : JRAAS, 2012-12-15; N = 70; Rigor 82/100): Telmisartan was significantly more effective than carvedilol in preventing recurrent AF episodes in hypertensive AF patients, despite a similar lowering of blood pressure.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: telmisartan → Rx: carvedilol → Rx: carvedilol-phosphate → Condition: encephalopathy-hypertensive → Condition: spider-angioma →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 22546623: Randomized Controlled Trial: A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients (N = 70)

3 of 3 Free Questions Remaining